Acetaminophen Use in Pregnancy: Evidence, Controversies, and Clinical Counseling

To review the current evidence regarding acetaminophen use in pregnancy, evaluate reported associations with adverse neurodevelopmental and reproductive outcomes, and provide an evidence-based framework for clinical counseling and decision-making.

A narrative review of the literature was performed, emphasizing large observational cohort studies, sibling-comparison analyses, pharmacokinetic data, and recent systematic reviews evaluating prenatal acetaminophen exposure and maternal-fetal outcomes.

Acetaminophen is the most commonly used analgesic and antipyretic in pregnancy, with 50-65% of pregnant individuals reporting use. Although observational studies have reported associations between prenatal acetaminophen exposure and adverse neurodevelopmental and reproductive outcomes, including attention-deficit/hyperactivity disorder, autism spectrum disorder, and cryptorchidism, these findings remain inconsistent and are subject to substantial confounding, particularly by indication. Large, methodologically rigorous studies incorporating sibling-controlled analyses have demonstrated attenuation or disappearance of these associations, suggesting that underlying maternal conditions may account for the observed risks. Pharmacokinetic studies demonstrate placental transfer of acetaminophen, although fetal metabolism differs because of limited glucuronidation capacity. Current pharmacologic evidence does not support a causal relationship between standard maternal acetaminophen use and premature fetal ductus arteriosus closure.

Current evidence does not support a causal relationship between typical prenatal acetaminophen exposure and adverse neurodevelopmental outcomes. Given the known risks of untreated maternal pain and fever, acetaminophen should remain the preferred first-line analgesic and antipyretic during pregnancy when clinically indicated. Patients should receive balanced, evidence-based counseling that acknowledges observational findings while emphasizing the limitations of current data. Use at the lowest effective dose for the shortest necessary duration remains appropriate clinical guidance.